-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compared with tablets, inhaled preparations can directly reach the lesions and have fewer adverse reactions.
Therefore, inhaled preparations are currently mainly used for the treatment of respiratory diseases
.
However, due to the high R&D threshold and technical barriers of inhalation preparations, not many domestic inhalants have been approved for marketing in the past few years, which also determines that there are very few inhalants submitted for supplementary applications for consistency evaluation
.
But it is worth noting that in recent years, especially since this year, a number of inhalant varieties have been approved for listing in China, and they have begun to grab the market of tens of billions of dollars
.
A few days ago, the website of the State Food and Drug Administration showed that the inhalation methacholine of Chia Tai Tianqing Pharmaceutical Group and the levosalbutamol hydrochloride atomized inhalation solution of Jiangsu Changtai Pharmaceutical Co.
Overrated
.
The data show that methacholine for inhalation is suitable for the diagnosis of bronchial airway hyperresponsiveness in adults without clinically significant asthma and children aged 5 years and over
.
The original research product has not yet been listed in China.
The methacholine for inhalation developed by Chia Tai Tianqing is the only provocative agent approved for bronchial provocation test in China
.
The levalbuterol hydrochloride atomized inhalation solution of Jiangsu Changtai Pharmaceutical Co.
, Ltd.
is used to treat or prevent bronchospasm caused by reversible airway obstructive diseases
.
Salbutamol is a short-acting β2-receptor agonist with rapid onset of action, and is currently widely used in clinical treatment of acute asthma attacks
.
In addition to the above-mentioned products, 5 inhalant varieties have been approved for marketing since the beginning of this year.
Among them, levalbuterol hydrochloride atomized inhalation solution has the most approvals, including four Trump Ruite Pharmaceuticals, Yangzhou Zhongbao Pharmaceuticals, Jiangsu Changtai There are 4 pharmaceutical companies and Jiangsu Dahongying Hengshun Pharmaceutical Co.
,
Ltd.
In addition, as of now, there are more than 100 products of inhalants (calculated by the name of the drug + the name of the declared company) under the new registration classification, involving more than 40 varieties (calculated by the name of the drug).
Four Trump Ruite, Chia Tai Tianqing and many other companies sprinted for the first imitation
.
The industry believes that the continuous listing of inhalation preparations is mainly due to the continuous expansion of the domestic inhalation market in recent years with the increase in the incidence of respiratory diseases in my country, and pharmaceutical companies are scrambling to deploy in this field.
.
It is understood that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminal inhalation drug market has been expanding year by year, and the annual growth rate has remained at double digits.
Breaking through the 20 billion mark, it reached 23.
68 billion yuan in 2019, a year-on-year increase of 10.
51%
.
However, it should be noted that although the inhalant market is constantly expanding, from the perspective of the current domestic inhalant market structure, the concentration is relatively high, and the total market share of the top 10 products accounts for more than 70%
.
Among them, the total market share of acetylcysteine solution for inhalation occupies "half of the country"
.
And more than half of them are foreign brands, and domestic brands account for less
.
Therefore, analysts believe that domestic brands still have a long way to go if they want to accelerate the replacement of original research
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Therefore, inhaled preparations are currently mainly used for the treatment of respiratory diseases
.
However, due to the high R&D threshold and technical barriers of inhalation preparations, not many domestic inhalants have been approved for marketing in the past few years, which also determines that there are very few inhalants submitted for supplementary applications for consistency evaluation
.
But it is worth noting that in recent years, especially since this year, a number of inhalant varieties have been approved for listing in China, and they have begun to grab the market of tens of billions of dollars
.
A few days ago, the website of the State Food and Drug Administration showed that the inhalation methacholine of Chia Tai Tianqing Pharmaceutical Group and the levosalbutamol hydrochloride atomized inhalation solution of Jiangsu Changtai Pharmaceutical Co.
Overrated
.
The data show that methacholine for inhalation is suitable for the diagnosis of bronchial airway hyperresponsiveness in adults without clinically significant asthma and children aged 5 years and over
.
The original research product has not yet been listed in China.
The methacholine for inhalation developed by Chia Tai Tianqing is the only provocative agent approved for bronchial provocation test in China
.
The levalbuterol hydrochloride atomized inhalation solution of Jiangsu Changtai Pharmaceutical Co.
, Ltd.
is used to treat or prevent bronchospasm caused by reversible airway obstructive diseases
.
Salbutamol is a short-acting β2-receptor agonist with rapid onset of action, and is currently widely used in clinical treatment of acute asthma attacks
.
In addition to the above-mentioned products, 5 inhalant varieties have been approved for marketing since the beginning of this year.
Among them, levalbuterol hydrochloride atomized inhalation solution has the most approvals, including four Trump Ruite Pharmaceuticals, Yangzhou Zhongbao Pharmaceuticals, Jiangsu Changtai There are 4 pharmaceutical companies and Jiangsu Dahongying Hengshun Pharmaceutical Co.
,
Ltd.
In addition, as of now, there are more than 100 products of inhalants (calculated by the name of the drug + the name of the declared company) under the new registration classification, involving more than 40 varieties (calculated by the name of the drug).
Four Trump Ruite, Chia Tai Tianqing and many other companies sprinted for the first imitation
.
The industry believes that the continuous listing of inhalation preparations is mainly due to the continuous expansion of the domestic inhalation market in recent years with the increase in the incidence of respiratory diseases in my country, and pharmaceutical companies are scrambling to deploy in this field.
.
It is understood that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) terminal inhalation drug market has been expanding year by year, and the annual growth rate has remained at double digits.
Breaking through the 20 billion mark, it reached 23.
68 billion yuan in 2019, a year-on-year increase of 10.
51%
.
However, it should be noted that although the inhalant market is constantly expanding, from the perspective of the current domestic inhalant market structure, the concentration is relatively high, and the total market share of the top 10 products accounts for more than 70%
.
Among them, the total market share of acetylcysteine solution for inhalation occupies "half of the country"
.
And more than half of them are foreign brands, and domestic brands account for less
.
Therefore, analysts believe that domestic brands still have a long way to go if they want to accelerate the replacement of original research
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
